Today: 9 June 2026
Browse Category

NASDAQ:EWTX 18 December 2025 - 30 December 2025

Edgewise Therapeutics stock steady midday after $3 million insider sale filing — what’s next for EWTX

Edgewise Therapeutics stock steady midday after $3 million insider sale filing — what’s next for EWTX

Edgewise Therapeutics shares rose 0.2% to $24.68 after a Form 144 filing showed officer Robert Michael Carruthers sold 116,665 shares for about $3.04 million on Dec. 26. The stock traded between $24.40 and $24.92 midday. The sale followed a Dec. 24 update on the company’s Phase 2 trial of EDG-7500 in hypertrophic cardiomyopathy. Biotech stocks broadly traded lower.
30 December 2025
·
Edgewise Therapeutics (EWTX) Stock Today: EDG-7500 Safety Update, Analyst Targets, and What Investors Are Watching Next

Edgewise Therapeutics (EWTX) Stock Today: EDG-7500 Safety Update, Analyst Targets, and What Investors Are Watching Next

Edgewise Therapeutics shares fell 4.7% to around $26.00 Friday after a clinical update on its EDG-7500 program in hypertrophic cardiomyopathy. The company reported no significant safety concerns in interim Phase 2 data, with over 40 participants enrolled and no clinically meaningful drops in ejection fraction. Biotech stocks lagged, with XBI down 1.16% and IBB off 0.86%, while broader indexes traded flat.
26 December 2025
·
Edgewise Therapeutics (EWTX) Stock Surges on EDG-7500 Safety Update as Wall Street Prepares to Reopen After Christmas

Edgewise Therapeutics (EWTX) Stock Surges on EDG-7500 Safety Update as Wall Street Prepares to Reopen After Christmas

Edgewise Therapeutics shares closed at $27.38 on December 24, up 26% after the company reported a favorable interim safety update for its EDG-7500 therapy in hypertrophic cardiomyopathy. Pre-market trading showed the stock at $27.46 as of 8:52 a.m. ET Friday. No clinically meaningful drops in ejection fraction or new atrial fibrillation were seen in the latest trial cohort. Regular U.S. trading resumes at 9:30 a.m. ET.
26 December 2025
···
Edgewise Therapeutics Stock (EWTX) Jumps on EDG-7500 CIRRUS-HCM Update: Dec. 24, 2025 News, Analyst Forecasts, and Key Catalysts

Edgewise Therapeutics Stock (EWTX) Jumps on EDG-7500 CIRRUS-HCM Update: Dec. 24, 2025 News, Analyst Forecasts, and Key Catalysts

Edgewise Therapeutics shares jumped 21% to $26.37 intraday Wednesday after the company reported positive interim safety data for its EDG-7500 therapy in hypertrophic cardiomyopathy. The update showed no clinically meaningful LVEF reductions and no LVEF drops below 50% among 20 patients, with one new-onset atrial fibrillation event disclosed. Over 40 participants have enrolled in Part D of the trial.
24 December 2025
··
Edgewise Therapeutics (EWTX) Stock News Today: What’s Driving the Volatility, Analyst Forecasts, and Key Catalysts (Dec. 22, 2025)

Edgewise Therapeutics (EWTX) Stock News Today: What’s Driving the Volatility, Analyst Forecasts, and Key Catalysts (Dec. 22, 2025)

Edgewise Therapeutics shares swung between $27.77 and $21.18 on Dec. 22, closing at $21.29 with volume over one million. The volatility followed a 20.8% surge on Dec. 19 and mixed analyst commentary, including JPMorgan raising its price target to $34 despite concerns over a $40.67 million quarterly loss.
22 December 2025
··
Edgewise Therapeutics (EWTX) Stock News, Forecasts and Analysis: What’s Driving the December 2025 Move and What Comes Next

Edgewise Therapeutics (EWTX) Stock News, Forecasts and Analysis: What’s Driving the December 2025 Move and What Comes Next

Edgewise Therapeutics shares surged 20.8% to $25.55 on December 19, 2025, trading over 3.1 million shares after a prior decline. No new company press releases or major updates were issued in the past 24–48 hours. The move followed routine equity grant news on December 2 and Q3 results on November 6. Analyst price targets remain above current levels.
21 December 2025
··
Edgewise Therapeutics (EWTX) Stock: Latest News, Analyst Forecasts, and What’s Driving the December 2025 Surge

Edgewise Therapeutics (EWTX) Stock: Latest News, Analyst Forecasts, and What’s Driving the December 2025 Surge

Edgewise Therapeutics shares surged 20.8% to $25.55 on December 19, 2025, amid heavy trading and technical breakout signals. The move follows recent investor conference appearances and ongoing focus on late-stage neuromuscular and cardiovascular drug programs. As of September 30, the company reported $563.3 million in cash and a Q3 net loss of $40.7 million.
20 December 2025
·
Edgewise Therapeutics (EWTX) Stock News and Forecast: Why Shares Rebounded on Dec. 19, 2025—and What Analysts Are Watching Next

Edgewise Therapeutics (EWTX) Stock News and Forecast: Why Shares Rebounded on Dec. 19, 2025—and What Analysts Are Watching Next

Edgewise Therapeutics shares jumped 8.79% to close at $23.01 on Dec. 19 after a volatile session and recent losses. The move coincided with elevated trading volume and options expiration. The company is advancing therapies for muscular dystrophies and cardiac conditions, with key clinical updates expected in late 2025 and beyond.
19 December 2025
···
Edgewise Therapeutics Stock (EWTX) Today: Why Shares Fell on Dec. 18, 2025, Plus Latest News, Analyst Forecasts, and Key Clinical Catalysts

Edgewise Therapeutics Stock (EWTX) Today: Why Shares Fell on Dec. 18, 2025, Plus Latest News, Analyst Forecasts, and Key Clinical Catalysts

Edgewise Therapeutics shares fell 8.8% to $20.35 on Thursday, with no new company news released that day. The stock traded between $20.33 and $22.81 on volume of about 1.25 million shares. EWTX remains 38% below its 52-week high and 92% above its 52-week low. The company’s recent updates include a December stock option grant and a November board appointment.
18 December 2025
··

Stock Market Today

  • Nuvalent Shares Surge Near $124 Following GSK's $10.6 Billion Buyout Offer
    June 9, 2026, 10:35 AM EDT. Nuvalent's stock jumped 38.9% to $122.93 after GSK announced a $10.6 billion cash acquisition at $124 per share, reflecting a 40% premium to the last close. The deal highlights GSK's strategic move to expand its oncology portfolio beyond its current 6% share of sales, aiming to capitalize on Nuvalent's two lung cancer drugs pending FDA decisions this year. The tender offer needs the approval of at least half of Nuvalent's Class A shares and U.S. antitrust clearance. Early analyst reactions included target price adjustments but echoed caution over valuation. Nuvalent's pipeline products could face competition from existing ALK-targeted therapies by Pfizer and Roche.

Latest articles

Autozi Shares Jump 400%, Filing Flags Risks for AZI

Autozi Shares Jump 400%, Filing Flags Risks for AZI

9 June 2026
Autozi Internet Technology shares soared over 400% to $5.69 in early Nasdaq trading after a 10-for-1 share consolidation slashed its share count to about 4.49 million, but the surge contrasts with a 63.1% revenue drop, 82.5% plunge in gross profit, and widened net loss, with the company warning of “substantial doubt” about its ability to continue as a going concern.
Redwire Shares Slip After $500 Million Stock Offering Filed

Redwire Shares Slip After $500 Million Stock Offering Filed

9 June 2026
Redwire Corp shares plunged 6.5% to $17.37 after launching a $500 million at-the-market stock program, raising dilution risks for investors as the company seeks flexible funding despite recent record backlog and strong revenue growth; the drop contrasted with gains at other space stocks, highlighting investor concern over potential share issuance.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

9 June 2026
Nuvalent shares soared 38.9% to $122.93, just below GSK’s $124-a-share cash offer after the $10.6 billion buyout was announced, as investors bet on the deal closing with Nuvalent’s two lead lung-cancer drugs already under FDA review and a 40% premium to the last closing price driving the morning’s merger-arb trade.
Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
Go toTop